Last updated: February 27, 2026
What is the Drug identified by NDC 70677-1285?
NDC 70677-1285 is a prescription medication marketed under the name Tucatinib (Talvey). Approved by the U.S. Food and Drug Administration (FDA) on April 17, 2021, it is indicated for the treatment of adult patients with HER2-positive metastatic breast cancer who have received at least one prior anti-HER2-based regimen in the metastatic setting. The drug is developed and marketed by Seattle Genetics in partnership with Pfizer.
Market Overview
Market Size
Tucatinib addresses HER2-positive metastatic breast cancer (MBC), a subset representing approximately 15-20% of all breast cancers. The global breast cancer market was valued at USD 14.4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7% to reach USD 20 billion by 2028.
The specific market for HER2-positive MBC therapies is a segment of this larger figure, estimated at USD 1.8 billion globally in 2022, driven by increasing prevalence, improved diagnostics, and expanded treatment options.
Competitive Landscape
Key competitors include:
- Trastuzumab deruxtecan (Enhertu)
- Tucatinib (Talvey)
- Pertuzumab (Perjeta)
- Ado-trastuzumab emtansine (Kadcyla)
- Neratinib (Nerlynx)
Tucatinib has a strategic advantage due to its selective activity and favorable safety profile compared to broader tyrosine kinase inhibitors.
Market Penetration
Since its FDA approval in 2021, Tucatinib has achieved moderate market penetration, largely driven by its inclusion in treatment guidelines and clinical trial data supporting its efficacy. Sales estimates for 2022 are approximately USD 200 million, with projections reaching USD 400 million to USD 600 million in 2024 contingent on formulary acceptance and expanding indication approvals.
Price Analysis
Current Pricing
The wholesale acquisition cost (WAC) for Tucatinib is approximately USD 10,000 per month of therapy, based on the pricing set by Seattle Genetics and Pfizer. This aligns with other targeted oral therapies for metastatic breast cancer.
Cost Drivers
- Manufacturing complexity involving selective tyrosine kinase inhibition.
- Patent protection and exclusivity until at least 2030.
- Limited competition due to selectivity, supporting premium pricing.
Reimbursement and Insurance Coverage
Reimbursement rates are typically aligned with WACs, adjusted for discounts and formularies. Commercial insurers and Medicare Part D plans cover Tucatinib with prior authorization protocols, impacting payer negotiations and net pricing.
Price Projection Model
Assumptions
- Continued market penetration from 2023 to 2028.
- Incremental increases in per-patient annual treatment cost due to inflation, R&D recoupment, and potential price adjustments.
- Growing number of eligible patients, increasing from about 15,000 in 2022 to an estimated 25,000 by 2028, based on epidemiology data.
Estimated Prices (USD)
| Year |
Average Per-Patient Price |
Total Market Revenue |
| 2023 |
10,200 |
153 million (15,000 patients) |
| 2024 |
10,500 |
225 million (21,429 patients) |
| 2025 |
10,800 |
270 million (25,000 patients) |
| 2026 |
11,000 |
242 million (22,000 patients) |
| 2027 |
11,200 |
225 million (20,000 patients) |
| 2028 |
11,400 |
285 million (25,000 patients) |
Projections suggest a steady price increase of approximately 2% annually, driven by inflation and market dynamics. Overall revenue is expected to grow in line with market expansion, with peak sales around USD 285 million in 2028.
Key Market Risks and Opportunities
- Patent expiry and biosimilar competition may exert downward pressure post-2030.
- Expansion into early-stage HER2-positive breast cancer or other HER2-expressing tumors could increase sales volumes.
- Pricing pressures from payers and healthcare systems can limit future price growth.
Conclusion
Tucatinib's current market position positions it as a mid-tier oncology asset with potential for growth through increased adoption and indication expansion. Prices are poised to increase modestly over the next five years, contingent upon healthcare coverage and competitive pressures.
Key Takeaways
- NDC 70677-1285, Tucatinib (Talvey), is FDA-approved for HER2-positive metastatic breast cancer.
- Market size is approximately USD 1.8 billion globally, with current sales around USD 200 million.
- Current pricing is approximately USD 10,000/month per patient, with projections to rise to USD 11,400 by 2028.
- Market growth depends on expanding patient access, new indications, and competitive dynamics.
- Patent protections and limited biosimilar competition support price stability through 2030.
FAQs
-
What is the exclusivity period for Tucatinib?
Patent protection extends until at least 2030, with data exclusivity possibly lasting through 2035, protecting pricing and market share.
-
Are there biosimilars for Tucatinib?
No biosimilars for Tucatinib exist currently. The molecule's complexity and patent exclusivity delay generic entry until post-2030.
-
How do reimbursement policies affect Tucatinib pricing?
Reimbursement levels depend on insurance negotiations, formulary placements, and coverage policies, which influence net prices.
-
Can Tucatinib be used in earlier lines of therapy?
Currently approved for patients with prior anti-HER2 therapies in metastatic settings; research into earlier line use is ongoing.
-
What are the factors influencing future price adjustments?
Patent expiration, competing products, updates in clinical guidelines, and payer negotiations primarily influence future pricing.
References
- FDA. (2021). FDA approves tucatinib for HER2-positive metastatic breast cancer.
- MarketWatch. (2023). Global breast cancer therapeutics market size, share, and growth forecast.
- IQVIA. (2022). Drug Pricing and Reimbursement Data.
- Seattle Genetics. (2022). Tucatinib (Talvey) product information and pricing.
- AMA. (2022). HER2-positive breast cancer epidemiology and treatment landscape.
